Aaron Balog graduated from Allegheny College in Western Pennsylvania in 1991 with a BS in organic chemistry. He then moved to the University of Pittsburgh where he worked with Professor Dennis Curran and received my Ph.D. in 1996. Having an interest in cancer research, he moved to Memorial Sloan-Kettering in New York where he joined the laboratory of Professor Samuel Danishefsky as an NIH Postdoctoral Fellow working on the synthesis of the epothilone family of natural products. Aaron then joined the Oncology Chemistry Department at Bristol-Myers Squibb in 1998, where he is currently a Senior Principal Scientist. He has worked on multiple oncology programs during his time at Bristol-Myers, including androgen receptor antagonist, CYP17-lyase and most recently, the indoleamine-2,3-dioxygenase inhibitor program.